Chinese Expert Consensus on Oral Drugs for the Treatment of Mature B‑Cell Lymphomas (2020 Edition)

Full English Version (Core Content & Full Text)

Basic Information

• Official Title: Chinese expert consensus on oral drugs for the treatment of mature B‑cell lymphomas (2020 edition)
• Organizers: Lymphoid Disease Group, Chinese Society of Hematology (CSH), Chinese Medical Association (CMA); jointly developed with CSCO Anti‑Lymphoma Alliance
• Published: Frontiers of Medicine (English), 2022, 16(5): 815–826; DOI: 10.1007/s11684‑021‑0891‑0
• Lead Authors: Suning Chen, Weili Zhao, Jianyong Li, Depei Wu (corresponding)
• Evidence Base: 62 peer‑reviewed articles (guidelines, trials, real‑world data) up to Dec 30, 2020; modified Delphi method (≥75% agreement for consensus; ≥90% = strong recommendation)
• Scope: Oral agents marketed in China for indolent and aggressive mature B‑cell lymphomas (BCL); focuses on monotherapy/combination, indications, safety, and clinical practice.

Abstract

1 Introduction

2 Methodology

• Initiation & Panel: Led by Lymphoid Disease Group, CSH, CMA; co‑developed with CSCO Anti‑Lymphoma Alliance. 34 experts (4 core, 30 voting) using modified Delphi.
• Literature Search: CSCO, NCCN, ESMO, ASH, PubMed, CNKI; included guidelines, trials, systematic reviews, meta‑analyses, real‑world studies, reviews up to Dec 30, 2020. 62 articles selected.
• Grading: Consensus = ≥75% agreement; strong recommendation = ≥90% agreement; moderate = 75%–89% agreement.
• Scope: Only oral drugs approved and marketed in China are covered.

3 Overview of Mature BCL

• Indolent BCL: CLL/SLL, WM/LPL, MZL, FL, and a subset of MCL; slow progression, chronic course.
• Aggressive BCL: DLBCL, high‑grade MCL, BL, and transformed lymphomas; rapid growth, curative intent with intensive therapy.
   
  Oral agents are increasingly integrated into first‑line, relapsed/refractory (R/R), and maintenance settings, especially for unfit, elderly, or chronic‑disease patients.

4 Oral Drugs for BCL (Approved in China)

4.1 Bruton’s Tyrosine Kinase Inhibitors (BTKi)

4.1.1 Ibrutinib

• Mechanism: Irreversible, first‑in‑class BTKi (also inhibits ITK, TEC); once‑daily oral.
• Chinese Approvals: R/R MCL; TN or R/R WM (monotherapy or + rituximab); CLL/SLL (TN/R/R).
• Evidence: Improves PFS and OS in MCL, WM, CLL/SLL (real‑world and trial data); long‑term follow‑up available; included in NRDL (2018).
• Key Toxicities: Atrial fibrillation/flutter, hypertension, bleeding, diarrhea, arthralgia, rash.

4.1.2 Zanubrutinib

• Mechanism: Selective, irreversible BTKi; optimized oral bioavailability, higher BTK occupancy, reduced off‑target effects.
• Chinese Approvals (2020): R/R MCL; R/R CLL/SLL (adults).
• Status: Not yet in NRDL; limited long‑term real‑world data; favorable cardiac and bleeding safety profile vs ibrutinib.

4.2 Immunomodulatory Drugs (IMiD)

4.2.1 Lenalidomide

• Mechanism: Immunomodulation (T/NK cell activation, anti‑angiogenesis, direct cytotoxicity); E3 ubiquitin ligase modulation.
• Chinese Approval: Multiple myeloma (lenalidomide + dexamethasone); no BCL indication in China (off‑label use in R/R FL, MCL, MZL per global data).
• Use in BCL: Mostly combination therapy (e.g., + rituximab, R² regimen); monotherapy efficacy limited.
• Toxicities: Neutropenia, thrombocytopenia, venous thromboembolism (VTE), fatigue, rash.

4.3 Traditional Oral Chemotherapies

4.3.1 Chlorambucil

• Mechanism: Nitrogen mustard alkylating agent; DNA interstrand cross‑links, inhibits replication.
• Indications (China): HL, NHL, CLL, WM, advanced ovarian cancer; NRDL‑listed, low‑cost, oral.
• Role: Historical first‑line for indolent lymphomas; low single‑agent response rates; largely replaced by targeted agents.

4.3.2 Cyclophosphamide

• Mechanism: Alkylating agent; DNA damage, apoptosis induction.
• Use: Component of combination regimens (e.g., CVP, CHOP); oral formulation used in low‑intensity or maintenance strategies for unfit patients.

4.3.3 Glucocorticoids (Oral)

• Mechanism: Lymphocytolysis, anti‑inflammatory/immune suppression.
• Role: Core component of chemoimmunotherapy (e.g., CHOP, bendamustine + rituximab + prednisone); limited efficacy as monotherapy; long‑term use associated with metabolic, infectious, and musculoskeletal toxicities.

5 Graded Recommendations for Oral Therapy in Mature BCL

5.1 Indolent BCL

5.1.1 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

• First‑line (TN, fit/unfit):
  • Strong: BTKi (ibrutinib, zanubrutinib) monotherapy (preferred for unfit, elderly, or high‑risk [del(17p), TP53 mut] patients).
  • Moderate: Chlorambucil ± anti‑CD20 (for frail patients with no access to BTKi).
   
• Relapsed/Refractory (R/R):
  • Strong: BTKi (ibrutinib, zanubrutinib) monotherapy (1L BTKi‑naïve).
  • Moderate: Lenalidomide ± anti‑CD20 (off‑label, for BTKi‑intolerant/failed).
   
• Maintenance:
  • Strong: BTKi continuous therapy (after response in TN/R/R).
  • Moderate: Lenalidomide maintenance (after chemoimmunotherapy, off‑label).
   

5.1.2 Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL)

• First‑line (TN):
  • Strong: Ibrutinib monotherapy (or + rituximab) (MYD88 L265P mut, unfit/fit).
  • Moderate: Bendamustine + rituximab ± oral prednisone (fit patients).
   
• R/R:
  • Strong: Ibrutinib monotherapy.
  • Moderate: Zanubrutinib monotherapy; lenalidomide + anti‑CD20 (off‑label).
   
• Maintenance:
  • Strong: Ibrutinib continuous therapy.
   

5.1.3 Follicular Lymphoma (FL, Grades 1–3A)

• First‑line (TN, advanced [III–IV], symptomatic):
  • Strong: Chemoimmunotherapy (e.g., BR, CVP) ± oral maintenance; lenalidomide + rituximab (R², off‑label) for unfit.
  • Moderate: Single‑agent oral chlorambucil (frail, low‑tumor burden).
   
• R/R:
  • Strong: Lenalidomide + rituximab (R², off‑label); BTKi (ibrutinib, off‑label).
  • Moderate: Oral alkylator (chlorambucil/cyclophosphamide) ± anti‑CD20 (palliative).
   
• Maintenance:
  • Strong: Lenalidomide maintenance (after R² or chemoimmunotherapy, off‑label).
   

5.1.4 Marginal Zone Lymphoma (MZL: NMZL, SMZL, EMZL)

• First‑line (TN, symptomatic/advanced):
  • Strong: Rituximab ± oral alkylator (chlorambucil/cyclophosphamide); ibrutinib (off‑label, for refractory/relapse).
  • Moderate: Single‑agent rituximab (low‑tumor burden).
   
• R/R:
  • Strong: Ibrutinib monotherapy (off‑label); lenalidomide + rituximab (off‑label).
   

5.1.5 Mantle Cell Lymphoma (MCL, Indolent Variant)

• First‑line (TN, non‑blastoid, low MIPI):
  • Strong: BTKi (ibrutinib, zanubrutinib) monotherapy (unfit/elderly).
  • Moderate: Chemoimmunotherapy + maintenance (fit).
   
• R/R:
  • Strong: BTKi (ibrutinib, zanubrutinib) monotherapy.
  • Moderate: Lenalidomide ± anti‑CD20 (off‑label).
   

5.2 Aggressive BCL

5.2.1 Diffuse Large B‑Cell Lymphoma (DLBCL)

• First‑line (TN, fit/unfit):
  • Strong: Chemoimmunotherapy (R‑CHOP‑21, standard); dose‑adjusted R‑EPOCH (high‑grade/double‑hit).
  • Moderate: Lenalidomide + R‑CHOP (R²‑CHOP, off‑label, ABC subtype); oral mini‑CHOP (unfit/frail).
   
• R/R (not candidate for CAR‑T/salvage transplant):
  • Strong: BTKi (ibrutinib, off‑label, ABC subtype); lenalidomide ± anti‑CD20 (off‑label).
  • Moderate: Oral single‑agent alkylator (palliative).
   
• Maintenance:
  • Strong: Lenalidomide maintenance (after first‑line response, high‑risk, off‑label).
   

5.2.2 Mantle Cell Lymphoma (MCL, Aggressive/Blastoid Variant)

• First‑line (TN, fit):
  • Strong: Intensive chemoimmunotherapy (e.g., R‑hyper‑CVAD/MA) + ASCT; BTKi (ibrutinib/zanubrutinib) post‑ASCT maintenance.
  • Moderate: BTKi + bendamustine + rituximab (unfit).
   
• R/R:
  • Strong: BTKi (ibrutinib, zanubrutinib) monotherapy; lenalidomide + anti‑CD20 (off‑label).
  • Moderate: Oral alkylator‑based combinations (palliative).
   

5.2.3 Burkitt Lymphoma (BL) & High‑Grade BCL (Double/Triple Hit)

• First‑line:
  • Strong: Short‑course, intensive chemoimmunotherapy (e.g., R‑CODOX‑M/R‑IVAC alternation); no role for single‑agent oral therapy.
   
• R/R (palliative):
  • Moderate: Oral targeted/immunomodulatory combinations (off‑label, compassionate use only).
   

6 Safety Management & Practical Considerations

6.1 BTKi Safety

• Atrial Fibrillation/Flutter: Monitor ECG at baseline, 3, 6 months, and periodically; manage with rate control (β‑blockers, diltiazem) ± anticoagulation (NOAC preferred). Hold BTKi for grade ≥3 AF; switch to zanubrutinib if recurrent.
• Bleeding: Avoid concurrent strong anticoagulants (e.g., warfarin); prefer NOACs at reduced dose. Hold BTKi before surgery (≥3–7 days). Prophylactic platelet transfusion for severe thrombocytopenia.
• Hypertension: Target BP <130/80 mmHg; use ACEi/ARB or dihydropyridine CCB (avoid non‑dihydropyridine CCB with ibrutinib).
• Diarrhea & Rash: Grade 1–2: supportive care; grade ≥3: dose hold/reduction.

6.2 Lenalidomide Safety

• Myelosuppression: Dose reduction/hold for grade ≥3 neutropenia/thrombocytopenia; G‑CSF prophylaxis.
• VTE Prophylaxis: Aspirin or low‑molecular‑weight heparin (standard‑risk); NOAC (high‑risk, e.g., prior VTE, diabetes).
• Tumor Flare: Monitor for fever, lymph node swelling; manage with short‑course steroids.

6.3 Traditional Chemotherapies

• Chlorambucil/Cyclophosphamide: Cumulative myelosuppression, infertility, secondary malignancies; limit cumulative dose.
• Glucocorticoids: Prophylaxis for osteoporosis, hyperglycemia, infection; taper long‑term use.

6.4 COVID‑19 & Oral Therapy

7 Monitoring & Follow‑Up

• Baseline: CBC, chemistry, LDH, β2‑microglobulin, bone marrow biopsy, imaging (CT/PET‑CT), ECG (BTKi), echocardiogram (if cardiac history).
• On‑Treatment:
  • BTKi: CBC q2–4 weeks, ECG q3–6 months, BP at each visit.
  • Lenalidomide: CBC q1–2 weeks (first 3 months), VTE risk assessment.
  • All: Tumor assessment q8–12 weeks (CT/PET‑CT).
   
• Maintenance: Clinical evaluation q3–6 months; imaging q6–12 months; long‑term toxicity monitoring (cardiac, secondary malignancy).

8 Conclusion

Full Text Access

• English Full Text: Frontiers of Medicine (Springer) DOI: 10.1007/s11684‑021‑0891‑0 (open access via journal website)
• Chinese Version: Published in Journal of Leukemia & Lymphoma (2020); available via DXY (Dingxiangyuan) Drugs Assistant, CMAB, and CNKI.
• Citation: Chen S, Zhao W, Li J, Wu D, et al. Chinese expert consensus on oral drugs for the treatment of mature B‑cell lymphomas (2020 edition). Front Med. 2022;16(5):815–826.